Repurposing of glatiramer acetate to treat cardiac ischemia in rodent models

Gal Aviel,Jacob Elkahal,Kfir Baruch Umansky,Hanna Bueno-Levy,Zachary Petrover,Yulia Kotlovski,Daria Lendengolts,David Kain,Tali Shalit,Lingling Zhang,Shoval Miyara,Matthias P Kramer,Yifat Merbl,Stav Kozlovski,Ronen Alon,Rina Aharoni,Ruth Arnon,David Mishali,Uriel Katz,Dean Nachman,Rabea Asleh,Offer Amir,Eldad Tzahor,Rachel Sarig
DOI: https://doi.org/10.1038/s44161-024-00524-x
2024-08-26
Abstract:Myocardial injury may ultimately lead to adverse ventricular remodeling and development of heart failure (HF), which is a major cause of morbidity and mortality worldwide. Given the slow pace and substantial costs of developing new therapeutics, drug repurposing is an attractive alternative. Studies of many organs, including the heart, highlight the importance of the immune system in modulating injury and repair outcomes. Glatiramer acetate (GA) is an immunomodulatory drug prescribed for patients with multiple sclerosis. Here, we report that short-term GA treatment improves cardiac function and reduces scar area in a mouse model of acute myocardial infarction and a rat model of ischemic HF. We provide mechanistic evidence indicating that, in addition to its immunomodulatory functions, GA exerts beneficial pleiotropic effects, including cardiomyocyte protection and enhanced angiogenesis. Overall, these findings highlight the potential repurposing of GA as a future therapy for a myriad of heart diseases.
What problem does this paper attempt to address?